Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.64 |
| ▸ | HPGDS | O60760 | 2/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | BCL9 | O00512 | 4/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958653 | 0.94 | USP30 (0.60) | USP30HPGDSPDE4BNR1H2RXRA | |
| SCHEMBL28834091 | 0.94 | USP30 (0.60) | USP30HPGDSPDE4BNR1H2RXRA | |
| SCHEMBL28834093 | 0.94 | USP30 (0.60) | USP30HPGDSPDE4BNR1H2RXRA | |
| SCHEMBL22944633 | 0.89 | USP30 (0.59) | USP30HPGDSACKR3PDE4BPRMT5 | |
| SCHEMBL6359096 | 0.89 | ALDH1A1 (0.56) | USP30HPGDSACKR3PDE4BPRMT5 | |
| SCHEMBL29386809 | 0.87 | GPR119 (0.55) | USP30HPGDSNR1H2RXRANR1H3 | |
| SCHEMBL12354143 | 0.87 | GPR119 (0.55) | USP30HPGDSNR1H2RXRANR1H3 | |
| SCHEMBL21425202 | 0.86 | BCL9 (0.56) | USP30HPGDSBCL9CTNNB1PDE4B | |
| SCHEMBL9962300 | 0.86 | USP30 (0.59) | USP30HPGDSBCL9CTNNB1PDE4B | |
| SCHEMBL4031537 | 0.86 | SIGMAR1 (0.54) | USP30BCL9CTNNB1PDE4BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | F2, PCSK9, F9 | USP30 1090/4885HPGDS 2266/4885ACKR3 4441/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | USP30 1090/4885HPGDS 2266/4885ACKR3 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.